Guidance Documents

This is a revision of a previously approved and posted Q&A (EO-DEA182), that was not considered guidance. This Q&A provides information regarding the training requirement included in CAA of 2023.  All practitioners, who are not solely a veterinarian, must attest to satisfying the training, credentialing, or educational requirements identified in the CAA in order to obtain a new or renewal DEA registration. 

This guidance document provides information regarding a Drug Enforcement Administration (DEA)-registered practitioner’s attestation of the training requirement in the recently enacted Consolidated Appropriations Act of 2023 (CAA).  While specifically targeted to the treatment of or screening for OUD, this training is required for all qualified practitioners applying for or renewing a registration to dispense controlled substances in schedules II-V.

This guidance document provides clarification regarding the regulatory requirement for persons engaging in regulated transactions in listed chemicals to report transactions involving an extraordinary quantity, an uncommon method of payment or delivery, or other circumstances indicating a potential use of listed chemicals in violation of the law.  This guidance is being sent via email to all Drug Enforcement Administration (DEA) listed chemical registrants and regulated persons.

This is a revision of previously approved and posted Q&As, that were published on March 31, 2020.  DEA-DC-9.  This  document replaces three of the questions posted within DEA-DC-9 and provides information regarding what EPCS is, remote identity proofing, and if qualified practitioners are allowed to use EPCS to issue prescriptions for CIII-V CS approved by the FDA for MOUD.

This Practitioner’s Manual has been prepared by the DEA, Diversion Control Division, as a guide to assist practitioners in their understanding of the federal Controlled Substances Act and its implementing regulations as they pertain to their profession.

Disposal of Controlled Substance Prescription Medications (Schedules II-V) Abandoned by Patients and Visitors at DEA-registered Hospital/Clinics, Narcotic Treatment Programs, and Practitioners’ and Mid-Level Practitioners’ Registered Locations.

This document informs DEA registrants impacted by the flexibilities DEA granted during the COVID-19 PHE, which flexibilities will automatically terminate at the conclusion of the COVID-19 PHE on May 11, 2023, and which flexibilities will remain in effect after May 11, 2023 under the Opioid Crisis PHE. The document also informs DEA registrants of newly published proposed rules intended to make some exceptions related to the COVID-19 PHE permanent.

This guidance document clarifies the requirement for Drug Enforcement Administration (DEA) registrant-transferors to use multiple single-sheet DEA Form 222s (order forms) when transferring schedule I or II controlled substances to a DEA registrant-transferee when the number of items being transferred exceeds the number of lines available on the order form.

This guidance document provides information regarding a practitioner’s use of existing Drug Enforcement Administration (DEA)-Form 222s after Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act (CAA) of 2023.

This guidance document, will be sent via email to all Drug Enforcement Administration registrants to provide clarification for disposal.